ES2149780T3 - Acidos salicilicos sustituidos para el tratamiento de enfermedades autoinmunes. - Google Patents
Acidos salicilicos sustituidos para el tratamiento de enfermedades autoinmunes.Info
- Publication number
- ES2149780T3 ES2149780T3 ES92924067T ES92924067T ES2149780T3 ES 2149780 T3 ES2149780 T3 ES 2149780T3 ES 92924067 T ES92924067 T ES 92924067T ES 92924067 T ES92924067 T ES 92924067T ES 2149780 T3 ES2149780 T3 ES 2149780T3
- Authority
- ES
- Spain
- Prior art keywords
- compound
- treatment
- autoimmune diseases
- salicilic
- acids
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 208000023275 Autoimmune disease Diseases 0.000 title abstract 2
- 239000002253 acid Substances 0.000 title 1
- 150000007513 acids Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 2
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical group C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical group [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical class [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 abstract 1
- 229940126601 medicinal product Drugs 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/76—Nitrogen atoms to which a second hetero atom is attached
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/20—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D261/14—Nitrogen atoms
- C07D261/16—Benzene-sulfonamido isoxazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D277/82—Nitrogen atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyridine Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9103397A SE9103397D0 (sv) | 1991-11-18 | 1991-11-18 | Nya substituerade salicylsyror |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2149780T3 true ES2149780T3 (es) | 2000-11-16 |
Family
ID=20384352
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES92924067T Expired - Lifetime ES2149780T3 (es) | 1991-11-18 | 1992-11-04 | Acidos salicilicos sustituidos para el tratamiento de enfermedades autoinmunes. |
Country Status (29)
| Country | Link |
|---|---|
| US (3) | US5302718A (enExample) |
| EP (1) | EP0613468B1 (enExample) |
| JP (1) | JP3259915B2 (enExample) |
| KR (1) | KR100253748B1 (enExample) |
| AT (1) | ATE194597T1 (enExample) |
| AU (1) | AU668528B2 (enExample) |
| CA (1) | CA2123697C (enExample) |
| DE (1) | DE69231252T2 (enExample) |
| DK (1) | DK0613468T3 (enExample) |
| EE (1) | EE03026B1 (enExample) |
| ES (1) | ES2149780T3 (enExample) |
| FI (1) | FI106857B (enExample) |
| GR (1) | GR3034585T3 (enExample) |
| HU (2) | HU221476B (enExample) |
| IL (1) | IL103665A (enExample) |
| LT (1) | LT3182B (enExample) |
| LV (1) | LV10246B (enExample) |
| MX (1) | MX9206647A (enExample) |
| MY (1) | MY130169A (enExample) |
| NO (1) | NO300805B1 (enExample) |
| NZ (1) | NZ244998A (enExample) |
| PT (1) | PT101068B (enExample) |
| RU (1) | RU2124501C1 (enExample) |
| SE (1) | SE9103397D0 (enExample) |
| SK (1) | SK282080B6 (enExample) |
| TW (1) | TW304944B (enExample) |
| UA (1) | UA42869C2 (enExample) |
| WO (1) | WO1993010094A1 (enExample) |
| ZA (1) | ZA928864B (enExample) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5514696A (en) * | 1992-05-06 | 1996-05-07 | Bristol-Myers Squibb Co. | Phenyl sulfonamide endothelin antagonists |
| GB9310095D0 (en) * | 1993-05-17 | 1993-06-30 | Zeneca Ltd | Therapeutic compounds |
| US5965732A (en) * | 1993-08-30 | 1999-10-12 | Bristol-Myers Squibb Co. | Sulfonamide endothelin antagonists |
| US5405842A (en) * | 1994-01-28 | 1995-04-11 | Silverman; Bernard A. | Treatment of steroid dependent asthmatics |
| GB9504854D0 (en) * | 1994-03-31 | 1995-04-26 | Zeneca Ltd | Nitrogen derivatives |
| US5612359A (en) * | 1994-08-26 | 1997-03-18 | Bristol-Myers Squibb Company | Substituted biphenyl isoxazole sulfonamides |
| US5846990A (en) * | 1995-07-24 | 1998-12-08 | Bristol-Myers Squibb Co. | Substituted biphenyl isoxazole sulfonamides |
| US6028052A (en) | 1995-09-18 | 2000-02-22 | Ligand Pharmaceuticals Incorporated | Treating NIDDM with RXR agonists |
| JPH09124620A (ja) * | 1995-10-11 | 1997-05-13 | Bristol Myers Squibb Co | 置換ビフェニルスルホンアミドエンドセリン拮抗剤 |
| US5856507A (en) * | 1997-01-21 | 1999-01-05 | Bristol-Myers Squibb Co. | Methods for the preparation of biphenyl isoxazole sulfonamides |
| CN1211183A (zh) | 1996-02-20 | 1999-03-17 | 布里斯托尔-迈尔斯斯奎布公司 | 联苯基异噁唑磺酰胺的制备方法 |
| US5939446A (en) * | 1996-04-09 | 1999-08-17 | Bristol-Myers Squibb Co. | Heteroaryl substituted phenyl isoxazole sulfonamide endothelin antagonists |
| JP3814742B2 (ja) * | 1996-10-18 | 2006-08-30 | イハラケミカル工業株式会社 | ４−フルオロサリチル酸類 |
| WO1998033781A1 (en) * | 1997-01-30 | 1998-08-06 | Bristol-Myers Squibb Company | Method for preventing or treating low renin hypertension by administering an endothelin antagonist |
| TW536540B (en) * | 1997-01-30 | 2003-06-11 | Bristol Myers Squibb Co | Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe |
| GB9804648D0 (en) | 1998-03-06 | 1998-04-29 | Zeneca Ltd | Chemical compounds |
| GB9805520D0 (en) * | 1998-03-17 | 1998-05-13 | Zeneca Ltd | Chemical compounds |
| GB9811427D0 (en) | 1998-05-29 | 1998-07-22 | Zeneca Ltd | Chemical compounds |
| CA2334545A1 (en) | 1998-06-12 | 1999-12-16 | Ligand Pharmaceuticals Incorporated | Treatment of anti-estrogen resistant breast cancer using rxr modulators |
| HK1039778A1 (zh) | 1999-03-19 | 2002-05-10 | Bristol-Myers Squibb Company | 制造联苯异恶唑基磺胺的方法 |
| DE60031699T2 (de) | 1999-09-04 | 2007-08-30 | Astrazeneca Ab | Hydroxyacetamidobenzolsulfonamidderivate |
| ES2307528T3 (es) | 1999-09-04 | 2008-12-01 | Astrazeneca Ab | Amidas como inhibidores para la piruvato deshidrogenasa. |
| CN1235877C (zh) | 1999-09-04 | 2006-01-11 | 阿斯特拉曾尼卡有限公司 | 升高丙酮酸脱氢酶活性的取代的n－苯基2－羟基－2－甲基－3,3,3－三氟代丙酰胺衍生物 |
| CA2307278A1 (en) * | 2000-04-28 | 2001-10-28 | University Of British Columbia | Use of n-heterocyclic substituted salicylic acids for inhibition of cellular uptake of cystine |
| AU2001254559A1 (en) * | 2000-04-28 | 2001-11-12 | The University Of British Columbia | Use of n-heterocyclic substituted salicylates for inhibition of cellular uptake of cystine |
| US6639082B2 (en) | 2000-10-17 | 2003-10-28 | Bristol-Myers Squibb Company | Methods for the preparation of biphenyl isoxazole sulfonamides |
| KR100360342B1 (ko) * | 2002-04-19 | 2002-11-13 | 박계정 | 밸런스 머신의 언밸런스 수정위치 및 수정량의 자동 보상방법 |
| EP1661889A4 (en) * | 2003-09-05 | 2009-08-05 | Ono Pharmaceutical Co | ANTAGONIST OF THE CHEMOKINE RECEPTOR AND ITS USE FOR MEDICAL PURPOSES |
| KR20060101772A (ko) * | 2003-12-19 | 2006-09-26 | 화이자 인코포레이티드 | 당뇨병 및 비만을 치료하기 위한,11-베타-하이드록시스테로이드 데하이드로게나제 유형1(11-베타-ｈｓｄ-1)의 저해제로서의벤젠설폰일아미노-피리딘-2-일 유도체 및 관련 화합물 |
| WO2006003517A1 (en) * | 2004-06-29 | 2006-01-12 | Warner-Lambert Company Llc | Combination therapies utilizing benzamide inhibitors of the p2x7 receptor |
| GB2421947A (en) * | 2005-01-07 | 2006-07-12 | Univ Southampton | Sulphonamide compounds for use as inhibitors of NF-kB |
| WO2007098169A1 (en) * | 2006-02-21 | 2007-08-30 | Amgen Inc. | Cinnoline derivatives as phosphodiesterase 10 inhibitors |
| RU2481329C2 (ru) * | 2008-06-23 | 2013-05-10 | Астеллас Фарма Инк. | Сульфонамидные соединения или их соли |
| AU2012220620A1 (en) * | 2011-02-23 | 2013-10-03 | Icahn School Of Medicine At Mount Sinai | Inhibitors of bromodomains as modulators of gene expression |
| TN2017000483A1 (en) | 2015-05-20 | 2019-04-12 | Amgen Inc | Triazole agonists of the apj receptor. |
| WO2017123826A1 (en) | 2016-01-14 | 2017-07-20 | Beth Israel Deaconess Medical Center, Inc. | Mast-cell modulators and uses thereof |
| WO2017192485A1 (en) | 2016-05-03 | 2017-11-09 | Amgen Inc. | Heterocyclic triazole compounds as agonists of the apj receptor |
| US10906890B2 (en) | 2016-11-16 | 2021-02-02 | Amgen Inc. | Triazole phenyl compounds as agonists of the APJ receptor |
| MA46827A (fr) | 2016-11-16 | 2019-09-25 | Amgen Inc | Composés de triazole à substitution cycloalkyle en tant qu'agonistes du récepteur apj |
| EP3541792B1 (en) | 2016-11-16 | 2020-12-23 | Amgen Inc. | Triazole furan compounds as agonists of the apj receptor |
| WO2018097945A1 (en) | 2016-11-16 | 2018-05-31 | Amgen Inc. | Heteroaryl-substituted triazoles as apj receptor agonists |
| WO2018093580A1 (en) | 2016-11-16 | 2018-05-24 | Amgen Inc. | Triazole pyridyl compounds as agonists of the apj receptor |
| US11191762B2 (en) | 2016-11-16 | 2021-12-07 | Amgen Inc. | Alkyl substituted triazole compounds as agonists of the APJ Receptor |
| WO2019089335A1 (en) | 2017-11-03 | 2019-05-09 | Amgen Inc. | Fused triazole agonists of the apj receptor |
| WO2019213006A1 (en) | 2018-05-01 | 2019-11-07 | Amgen Inc. | Substituted pyrimidinones as agonists of the apj receptor |
| CN111056978B (zh) * | 2019-12-13 | 2021-01-19 | 西安交通大学 | 一种磺酰胺类化合物及其制备方法和应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2396145A (en) | 1940-12-14 | 1946-03-05 | Pharmscia Ab | Heterocyclic sulphonamido azo compounds |
| BE791889A (fr) * | 1971-11-26 | 1973-05-24 | Pharmacia Ab | Nouveaux derives de la pyridine |
| AU567140B2 (en) * | 1984-01-06 | 1987-11-12 | Shionogi & Co., Ltd. | Sulphonamido-benzamide derivatives |
| US4663334A (en) * | 1985-12-11 | 1987-05-05 | Mcneilab, Inc. | Heteroaromatic acetylenes useful as antihypertensive agents |
| US4897397A (en) * | 1988-12-16 | 1990-01-30 | Schering Corporation | Aryl-alkynoic, alkenoic or alkanoic compounds and compositions useful as antiallergy and anti-inflammatory agents |
-
1991
- 1991-11-18 SE SE9103397A patent/SE9103397D0/xx unknown
-
1992
- 1992-11-03 NZ NZ244998A patent/NZ244998A/en not_active IP Right Cessation
- 1992-11-04 ES ES92924067T patent/ES2149780T3/es not_active Expired - Lifetime
- 1992-11-04 SK SK547-94A patent/SK282080B6/sk unknown
- 1992-11-04 UA UA94005499A patent/UA42869C2/uk unknown
- 1992-11-04 JP JP50919193A patent/JP3259915B2/ja not_active Expired - Fee Related
- 1992-11-04 KR KR1019940701664A patent/KR100253748B1/ko not_active Expired - Fee Related
- 1992-11-04 CA CA002123697A patent/CA2123697C/en not_active Expired - Fee Related
- 1992-11-04 DK DK92924067T patent/DK0613468T3/da active
- 1992-11-04 WO PCT/SE1992/000758 patent/WO1993010094A1/en not_active Ceased
- 1992-11-04 HU HU9401391A patent/HU221476B/hu not_active IP Right Cessation
- 1992-11-04 EP EP92924067A patent/EP0613468B1/en not_active Expired - Lifetime
- 1992-11-04 DE DE69231252T patent/DE69231252T2/de not_active Expired - Fee Related
- 1992-11-04 AT AT92924067T patent/ATE194597T1/de not_active IP Right Cessation
- 1992-11-04 AU AU29589/92A patent/AU668528B2/en not_active Ceased
- 1992-11-04 RU RU94028109A patent/RU2124501C1/ru not_active IP Right Cessation
- 1992-11-06 IL IL10366592A patent/IL103665A/xx not_active IP Right Cessation
- 1992-11-09 US US07/973,753 patent/US5302718A/en not_active Expired - Lifetime
- 1992-11-13 LV LVP-92-202A patent/LV10246B/xx unknown
- 1992-11-17 PT PT101068A patent/PT101068B/pt not_active IP Right Cessation
- 1992-11-17 LT LTIP229A patent/LT3182B/lt not_active IP Right Cessation
- 1992-11-17 ZA ZA928864A patent/ZA928864B/xx unknown
- 1992-11-17 MY MYPI92002100A patent/MY130169A/en unknown
- 1992-11-18 MX MX9206647A patent/MX9206647A/es not_active IP Right Cessation
- 1992-11-27 TW TW081109532A patent/TW304944B/zh active
-
1993
- 1993-10-07 US US08/132,874 patent/US5403930A/en not_active Expired - Fee Related
-
1994
- 1994-05-13 NO NO941799A patent/NO300805B1/no unknown
- 1994-05-17 FI FI942289A patent/FI106857B/fi not_active IP Right Cessation
- 1994-11-02 EE EE9400111A patent/EE03026B1/xx not_active IP Right Cessation
- 1994-12-29 US US08/365,869 patent/US5556855A/en not_active Expired - Fee Related
-
1995
- 1995-06-28 HU HU95P/P00492P patent/HU211163A9/hu unknown
-
2000
- 2000-10-09 GR GR20000402274T patent/GR3034585T3/el not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2149780T3 (es) | Acidos salicilicos sustituidos para el tratamiento de enfermedades autoinmunes. | |
| UY37848A (es) | Sulfonilureas y sulfoniltioureas útiles como inhibidores de nlrp3 | |
| UY37795A (es) | Sulfonilureas y sulfoniltioureas útiles como inhibidores de nlrp3 | |
| MX2020004423A (es) | Nuevos compuestos de sulfonamida carboxamida. | |
| MX2024015479A (es) | Moduladores de la via de respuesta integrada al estres | |
| MX2020001778A (es) | Nuevos compuestos de sulfonamida carboxamida. | |
| CO2020014296A2 (es) | Derivado policíclico de piridona | |
| JOP20220131A1 (ar) | مركبات أمينو كينولون تحمل بدائل تستخدم كمثبطات لـ dgkalpha من أجل تنشيط المناعة | |
| UY37363A (es) | Sulfonilureas y compuestos relacionados y sus usos | |
| AR030507A1 (es) | Compuesto de pirazolopiridina y los usos farmaceuticos del mismo | |
| ECSP034534A (es) | Nuevos tiadiazoles y oxadiazoles y su uso como inhibidores de fosfodiesterasa-7 | |
| PH12020550168A1 (en) | Griseofulvin compound and pharmaceutical use thereof | |
| UY30300A1 (es) | Compuestos triarílicos y sus derivados | |
| MX2022003903A (es) | Optimizacion del nivel de conservantes para composiciones para el cuidado personal. | |
| PE20080378A1 (es) | Derivados tiofeno-pirazolalcanamida con actividad sobre los receptores ampa | |
| MX2022002339A (es) | Derivados de alfa-d-galactopiranosido. | |
| MX2021012904A (es) | Moduladores de la via de respuesta al estres integrada. | |
| CR6503A (es) | Derivados de- 1-trifluorometil-4-hidroxi-7-piperidinil-aminometiclcromano | |
| PL431613A1 (pl) | Związek do zastosowania jako lek, inhibitor kinazy PERK oraz jego zastosowanie do zapobiegania i leczenia chorób neurodegeneracyjnych zależnych od stresu retikulum endoplazmatycznego | |
| ES2101171T3 (es) | Derivados de tiadiazol para el tratamiento de estados depresivos. | |
| ECSP014089A (es) | Derivados de tropano utiles en terapia | |
| BR112022012352A2 (pt) | Novo derivado de amida útil como inibidor de diacilglicerol aciltransferase 2 e uso do mesmo | |
| UY26949A1 (es) | Nuevos tidiazoles y oxadiazoles y su uso como inhibidores de fosfodiesterasa - 7 | |
| AR112263A1 (es) | Derivados de sulfonamidas útiles en el tratamiento de enfermedades mediadas por la inhibición de nlrp3 | |
| ES2116528T3 (es) | Nuevo compuesto, la leustroducsina h, su preparacion y su utilizacion terapeutica. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG2A | Definitive protection |
Ref document number: 613468 Country of ref document: ES |